Loading
Led KEYNOTE-A18, which showed adding pembrolizumab to chemoradiotherapy improves survival in locally advanced cervical cancer.
Domenica Lorusso was principal investigator of KEYNOTE-A18, the ENGOT trial showing pembrolizumab with chemoradiotherapy improves progression-free and overall survival in high-risk locally advanced cervical cancer, the first systemic addition to chemoradiation to do so in two decades. She has led the MITO group's ovarian and endometrial trials and co-led studies of trastuzumab deruxtecan in gynaecological cancers.
The survival gain turns the earlier progression-free survival result into a clear reason to offer pembrolizumab with and after chemoradiotherapy to women with node-positive or stage III-IVA cervical cancer. Because cervical cancer is concentrated in low- and middle-income countries, the benefit reaches most women only if pricing and access follow.
Women with locally advanced cervical cancer that is node-positive or stage III-IVA can be offered pembrolizumab alongside and after chemoradiotherapy to lower the chance of relapse. The result matters most in countries where cervical cancer is common but immunotherapy access is poorest, so its global impact depends on pricing and health-system capacity. It does not apply to early-stage disease treated with surgery or to lower-risk locally advanced disease without nodal involvement.
Shares PD-1, Cervical cancer, Ovarian cancer, Pembrolizumab and the tags cervical, immunotherapy.
Shares KEYNOTE-A18 / ENGOT-cx11 / GOG-3047, KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (overall survival), KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (progression-free survival), Cervical cancer.
Shares KEYNOTE-A18 / ENGOT-cx11 / GOG-3047, PD-1, Cervical cancer, Ovarian cancer and the tag cervical.
Shares PD-1, Immune checkpoint inhibitors and the tags immunotherapy, italy.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Endometrial cancer, PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (overall survival), KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (progression-free survival), Endometrial cancer, Cervical cancer.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.